STAAR Surgical Management
Management criteria checks 2/4
STAAR Surgical's CEO is Steve Farrell, appointed in Feb 2025, has a tenure of less than a year. directly owns 0.066% of the company’s shares, worth $614.84K. The average tenure of the management team and the board of directors is 1.4 years and 3.6 years respectively.
Key information
Steve Farrell
Chief executive officer
US$295.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.07% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Apr 05
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Feb 14STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Feb 12STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jan 31STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
Nov 29Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
Oct 24
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Sep 05Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
Aug 05The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
Jul 12Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
May 27Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Apr 26STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
Apr 05STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue
Mar 25STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade
Mar 13STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump
Mar 07Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
Jan 31With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For
Jan 05Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)
Nov 30Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?
Nov 12Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?
Oct 25Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes
Aug 24Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?
Jul 02Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?
Jun 17Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
May 13A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Mar 26STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital
Mar 12Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?
Feb 13Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
Jan 28Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Dec 15The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising
Dec 01CEO
Steve Farrell (59 yo)
Mr. Stephen C. Farrell, also known as Steve, CFA, is Chief Executive Officer of STAAR Surgical Company from February 26, 2025 and serves as its Director and had been its Independent Director since January...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$295.01k | 0.066% $ 614.8k | |
| President & COO | 2.1yrs | US$2.90m | 0.025% $ 234.2k | |
| Senior VP | 1.4yrs | US$2.13m | 0.022% $ 201.8k | |
| Chief Development Officer and Chief Clinical | 2.1yrs | US$2.31m | 0.020% $ 182.4k | |
| Advisor | less than a year | US$7.82m | 0.11% $ 1.0m | |
| Interim Chief Financial Officer | less than a year | US$755.30k | no data | |
| Vice President of Investor Relations & Corporate Development | no data | no data | no data | |
| Chief Marketing Officer | 1yr | no data | no data | |
| Senior Vice President of Commercial Operations - North America & APAC | 8.5yrs | US$2.54m | 0% $ 0 | |
| Chief Medical Officer | 7.6yrs | US$2.48m | 0% $ 0 | |
| Senior Vice President of Operations | no data | no data | no data |
Experienced Management: STAA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.3yrs | US$295.01k | 0.066% $ 614.8k | |
| Independent Director | 10.7yrs | US$52.45k | 0.00096% $ 8.9k | |
| Independent Director | 2.9yrs | US$256.54k | 0.014% $ 133.9k | |
| Independent Director | 1.4yrs | US$246.96k | 0.0047% $ 43.5k | |
| Member of Optometric Advisory Council | 16.5yrs | no data | no data | |
| Independent Director | 1.2yrs | US$275.80k | 0.0040% $ 36.7k | |
| Independent Director | 1.2yrs | US$286.26k | 0.0026% $ 24.2k | |
| Independent Board Chair | 4.3yrs | US$250.01k | 0.0058% $ 53.4k |
Experienced Board: STAA's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 20:24 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/28 |
| Annual Earnings | 2024/12/27 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STAAR Surgical Company is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
| Michael Gorman | BTIG |
| John Young | Canaccord Genuity |